Join our daily newsletter At The Bell to receive exclusive market insights
- CardieX’s (CDX) subsidiary teams up with Andiwn Scientific for a global clinical trial of ATCOR XCEL device and data management services
- ATCOR has entered a new global clinical trial services agreement with Andwin Scientific to support Syneos Health and Philip Morris for the lease of ATCOR XCEL devices
- ATCOR will also provide data management services for the clinical trial, sponsored by Philip Morris
- The total revenue for the devices is estimated to sit around $1.3 million over a 19-month period, with the majority to be recognised in 2022
- CardieX is up 2.27 per cent, trading at 4.5 cents at 1:50 pm AEDT
CardieX’s (CDX) subsidiary has teamed up with Andiwn Scientific for a global clinical trial of ATCOR XCEL device and data management services.
ATCOR has entered a new global clinical trial services agreement with Andwin Scientific to support Syneos Health and cigarette and tobacco manufacturer, Philip Morris, for the lease of ATCOR XCEL devices. ATCOR will also provide data management services for the clinical trial, sponsored by Philip Morris.
The ATCOR XCEL device will be used for the trial to determine arterial health outcomes and arterial stiffness, both of which are considered key biomarkers of arterial health.
Syneos will run and manage the trial, while Andwin Scientific will provide the equipment, with the trial set to take place across 22 sites.
Under the agreement, Andwin has issued the first purchase order to ATCOR for the trial. The total revenue is estimated to sit around $1.3 million over a 19-month period, with the majority to be recognised in 2022.
“We continue to see validation of our industry-leading SphygmoCo® technology globally with multiple on-going clinical trials relying on our XCEL device for advanced medical grade arterial health parameters,” CEO and Managing Director Craig Cooper said.
“It’s this same technology that also powers our next generation of devices and partnerships with the upcoming Mobvoi smartwatch, as well as multiple new proposed devices in development for 2022.”
CardieX was up 2.27 per cent, trading at 4.5 cents at 1:50 pm AEDT.
-1200x645-380x200.jpg)
